Long-Term Bortezomib Treatment Reduces Allergen-Specific IgE but Fails to Ameliorate Chronic Asthma in Mice
Authors:
- Michael WegmannMWMichael Wegmann
- Lars LundingLLLars Lunding
- Zane OrinskaZOZane Orinska
- David M. WongDWDavid M. Wong
- Rudolf A. ManzRMRudolf A. Manz
- Heinz FehrenbachHeinz Fehrenbach
- 29 December 2011
- journal article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 158 (1) , 43-53
Abstract
Background: Allergen-specific immunoglobulin (Ig) E initiates the effector cascade of allergic asthma and has been identified as a valuable target for therapeutic treatment of this disease. The proteasome inhibitor bortezomib was previously shown to deplete Ig-secreting plasma cells and to efficiently suppress Ig serum titers. The present study aimed at evaluating the therapeutic potential of the proteasome inhibitor bortezomib in allergic bronchial asthma. Methods: To address this question, a chronic experimental asthma mouse model was used in a therapeutic setting. Mice were sensitized to ovalbumin (OVA) and challenged with OVA aerosol for 12 weeks. After 6 weeks of challenge, bortezomib treatment was started and continued for 1 week (short-term) or 6 weeks (long-term) with a dosage of 0.75 mg/kg body weight twice a week. Lung function, lung histology, Ig serum titers and plasma cell numbers were assessed. Results: Whereas short-term treatment lowered bronchoalveolar lavage eosinophils, long-term treatment considerably reduced serum titers of anti-OVA IgE in mice with chronic experimental asthma. However, neither short-term nor long-term treatment significantly reduced plasma cell numbers, anti-OVA IgG1 serum titers or allergic airway inflammation or ablated airway hyperresponsiveness. Conclusion: Our results suggest that bortezomib treatment has only limited value as plasma cell-depleting therapy against allergic bronchial asthma.Keywords
This publication has 33 references indexed in Scilit:
- Allergy for a Lifetime?Allergology International, 2010
- Induction of long-lived allergen-specific plasma cells by mucosal allergen challengeJournal of Allergy and Clinical Immunology, 2009
- AsthmaNew England Journal of Medicine, 2009
- New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007Journal of Allergy and Clinical Immunology, 2008
- The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritisNature Medicine, 2008
- Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: First reported caseLeukemia Research, 2008
- Involvement of eosinophils in the onset of asthmaJournal of Allergy and Clinical Immunology, 2008
- Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome InhibitionCancer Research, 2007
- Involvement of distal airways in a chronic model of experimental asthmaClinical & Experimental Allergy, 2005
- Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthmaProceedings of the National Academy of Sciences, 1997